[SCHEDULE 13G] Reneo Pharmaceuticals, Inc. Common Stock SEC Filing

Rhea-AI Filing Summary

Cantor Fitzgerald entities reported beneficial ownership of 669,539 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 5.2% of the outstanding shares. The percentage is calculated using 12,823,872 shares outstanding as of May 5, 2025. The filing lists four related reporting persons (Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., and CF Group Management, Inc.) that together may be deemed to beneficially own the reported shares through shared voting and dispositive power, with shared voting power and shared dispositive power of 669,539 and no sole voting or dispositive power. The filing notes a related transaction in which Howard W. Lutnick agreed to divest certain interests and agreements were entered May 16, 2025 to transfer voting shares of CF Group Management to trusts controlled by Brandon G. Lutnick; those closings remain subject to customary conditions and regulatory approvals. The statement is certified and signed by authorized officers on August 14, 2025.

Positive

• Full disclosure of beneficial ownership by related Cantor Fitzgerald entities (669,539 shares, 5.2% of class)
• Clear description of inter-entity control and record-holder relationships among CF entities
• Filing includes certification and signatures dated August 14, 2025 and a joint filing agreement exhibit

Negative

• None.

Insights

Financial Analyst

TL;DR: A registered broker-dealer group disclosed a modestly material 5.2% stake in OnKure, reported through shared voting/dispositive arrangements.

The Schedule 13G shows Cantor Fitzgerald-affiliated entities collectively hold 669,539 Class A shares (5.2% of 12.82M outstanding). The position is reported under passive ownership rules rather than an active 13D control filing, indicating no intent to influence control is asserted. Shared voting and dispositive power across related entities is disclosed, and record ownership resides with Cantor Fitzgerald & Co. The filing clarifies internal ownership/control relationships and notes pending trust transfers related to the Lutnick family, subject to customary closing conditions and regulatory approvals. For investors, this is a transparency disclosure of a non-controlling stake by a prominent brokerage group.

Corporate Governance Expert

TL;DR: Governance disclosure is thorough: related-party control links and pending transfers are clearly described and certified.

The submission identifies the reporting persons, their organizational jurisdictions, and how indirect control flows among entities (CF&Co., CFS, CFLP, CFGM). It includes a disclaimer of beneficial ownership except to the extent of any pecuniary interest and documents an agreed transfer of CFGM voting shares from Howard W. Lutnick to trusts controlled by Brandon G. Lutnick, noting regulatory approvals are required. Signatures of authorized officers and a joint filing agreement exhibit are included, meeting formal SEC disclosure expectations for group/related-party holdings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

OnKure Therapeutics Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

68277Q105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

Cantor Fitzgerald Securities

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 669,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 669,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

669,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: * N/A

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

Cantor Fitzgerald & Co.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 669,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 669,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

669,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: * N/A

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

Cantor Fitzgerald, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 669,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 669,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

669,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: * N/A

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

CF Group Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 669,539.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 669,539.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

669,539.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: * N/A

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OnKure Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 6707 Winchester Circle, Suite 400 Boulder, CO 80301
Item 2.
(a)	Name of person filing: Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., CF Group Management and Inc. (collectively, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: 110 East 59th Street New York, New York 10022
(c)	Citizenship: Cantor Fitzgerald & Co. is a general partnership formed in New York, Cantor Fitzgerald Securities is a general partnership formed in New York, Cantor Fitzgerald, L.P. is a Delaware limited partnership, CF Group Management, Inc. is a New York corporation.
(d)	Title of class of securities: Class A Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 68277Q105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference. As of June 30, 2025, the Reporting Persons may be deemed to beneficially own an aggregate of 669,539 shares of Class A Common Stock, par value $0.0001 per share ("Common Stock") of OnKure Therapeutics, Inc. (the "Issuer"), representing 5.2% of the Issuer's outstanding Common Stock. The percentage of the Common Stock held by the Reporting Persons is based on 12,823,872 shares of Common Stock outstanding as of May 5, 2025 as reported in the Issuer's Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Securities and Exchange Commission on May 6, 2025. Cantor Fitzgerald & Co. ("CF&Co.") is the record holder of certain of the securities reported herein. Cantor Fitzgerald Securities ("CFS") controls the managing general partner of CF&CO. Cantor Fitzgerald, L.P. ("CFLP") indirectly controls each of CFS and CF&CO. CFLP is controlled by CF Group Management, Inc. ("CFGM"), its managing general partner. As such, each of CFS, CFLP and CFGM may be deemed to have beneficial ownership of the securities directly held by CF&CO. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly. On May 16, 2025, Howard W. Lutnick, in his capacity as trustee of a trust, entered into agreements to sell to trusts controlled by Brandon G. Lutnick all of the voting shares of CFGM. Following the closing of the transactions contemplated by such agreements, Brandon G. Lutnick will be deemed to have voting or dispositive power over the Common Stock held by CFGM. The closings of the transactions contemplated by such agreements are subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. The transactions described herein follow Howard W. Lutnick's agreement to divest his interests in CFLP to comply with U.S. government ethics rules in connection with his appointment as the U.S. Secretary of Commerce.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cantor Fitzgerald Securities

Signature:	/s/ Pascal Bandelier
Name/Title:	Pascal Bandelier/Co-Chief Executive Officer
Date:	08/14/2025

Cantor Fitzgerald & Co.

Signature:	/s/ Pascal Bandelier
Name/Title:	Pascal Bandelier/Co-Chief Executive Officer
Date:	08/14/2025

Cantor Fitzgerald, L.P.

Signature:	/s/ Brandon Lutnick
Name/Title:	Brandon Lutnick/Chairman & Chief Executive Officer
Date:	08/14/2025

CF Group Management, Inc.

Signature:	/s/ Brandon Lutnick
Name/Title:	Brandon Lutnick/Chairman & Chief Executive Officer
Date:	08/14/2025

Exhibit Information

Exhibit No. Description 99.1 Joint Filing Agreement, dated as of August 14, 2025, by and among the Reporting Persons

FAQ

How many OnKure Therapeutics (Class A) shares do Cantor Fitzgerald entities report owning?

The reporting persons report beneficial ownership of 669,539 shares of OnKure Therapeutics Class A Common Stock.

What percentage of OnKure's outstanding stock does 669,539 shares represent?

The filing states this represents 5.2% of the class based on 12,823,872 shares outstanding as of May 5, 2025.

Which Cantor Fitzgerald entities filed the Schedule 13G?

The filers are Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., and CF Group Management, Inc.

Does the filing indicate any intent to influence control of OnKure?

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control, consistent with a Schedule 13G passive filing.

Are there any related-party transactions or ownership changes noted?

Yes. On May 16, 2025, agreements were entered for Howard W. Lutnick to sell voting shares of CF Group Management to trusts controlled by Brandon G. Lutnick; closings are subject to customary conditions and regulatory approvals.

When was this Schedule 13G signed?

Authorized signatures on the filing are dated August 14, 2025.